NCT02790437View on ClinicalTrials.gov

A Phase II Study to Evaluate the Efficacy of IdeS to Desensitize Transplant Patients With a Positive Crossmatch Test

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

December 12, 2017

Study Completion Date

July 3, 2018

Conditions
Kidney Failure, Chronic
Interventions
DRUG

IdeS

One dose of 0.25 mg/kg BW IdeS on study day 0. If negative crossmatch is not achieved, a second dose can be given within 2 days of the first infusion.

PROCEDURE

Kidney transplantation

Performed following IdeS treatment

Trial Locations (5)

10016

New York University School of Medicine, New York

21205

The Johns Hopkins Hospital, Baltimore

75185

Uppsala University Hospital, Uppsala

75743

Necker Hospital, Paris

90048

Cedars-Sinai Medical Center, Los Angeles

Sponsors

Lead Sponsor

Hansa Biopharma AB
All Listed Sponsors
lead

Hansa Biopharma AB

INDUSTRY

NCT02790437 - A Phase II Study to Evaluate the Efficacy of IdeS to Desensitize Transplant Patients With a Positive Crossmatch Test | Biotech Hunter | Biotech Hunter